Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013).

La Torre G, Mannocci A, Saulle R, Colamesta V, Meggiolaro A, Mipatrini D, Sinopoli A.

Hum Vaccin Immunother. 2016 Sep;12(9):2299-311. doi: 10.1080/21645515.2016.1166328.

PMID:
27105443
2.

Prevention of hepatitis B.

Chang MH, Chen DS.

Cold Spring Harb Perspect Med. 2015 Mar 2;5(3):a021493. doi: 10.1101/cshperspect.a021493. Review.

3.

Hepatitis B virus infection in post-vaccination South Africa: occult HBV infection and circulating surface gene variants.

Amponsah-Dacosta E, Lebelo RL, Rakgole JN, Selabe SG, Gededzha MP, Mayaphi SH, Powell EA, Blackard JT, Mphahlele MJ.

J Clin Virol. 2015 Feb;63:12-7. doi: 10.1016/j.jcv.2014.11.032.

4.

Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose.

Mendy M, Peterson I, Hossin S, Peto T, Jobarteh ML, Jeng-Barry A, Sidibeh M, Jatta A, Moore SE, Hall AJ, Whittle H.

PLoS One. 2013;8(3):e58029. doi: 10.1371/journal.pone.0058029.

5.

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

Cavenaugh JS, Awi D, Mendy M, Hill AV, Whittle H, McConkey SJ.

PLoS One. 2011 Feb 15;6(2):e14626. doi: 10.1371/journal.pone.0014626.

6.

Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Amanna IJ, Slifka MK.

Virology. 2011 Mar 15;411(2):206-15. doi: 10.1016/j.virol.2010.12.016. Review.

7.

Costs and efficacy of public health interventions to reduce aflatoxin-induced human disease.

Khlangwiset P, Wu F.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2010 Jul;27(7):998-1014. doi: 10.1080/19440041003677475. Review.

8.

Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia.

Mendy ME, McConkey SJ, Sande van der MA, Crozier S, Kaye S, Jeffries D, Hall AJ, Whittle HC.

Virol J. 2008 Apr 16;5:49. doi: 10.1186/1743-422X-5-49.

9.

Host genetic factors and vaccine-induced immunity to hepatitis B virus infection.

Hennig BJ, Fielding K, Broxholme J, Diatta M, Mendy M, Moore C, Pollard AJ, Rayco-Solon P, Sirugo G, van der Sande MA, Waight P, Whittle HC, Zaman SM, Hill AV, Hall AJ.

PLoS One. 2008 Mar 26;3(3):e1898. doi: 10.1371/journal.pone.0001898. Erratum in: PLoS One. 2011;6(2). doi: 10.1371/annotation/0d903d46-1104-43b8-ae6b-4f2343bb3357.

10.

Long-term persistence of T cell memory to HBsAg after hepatitis B vaccination.

Wang RX, Boland GJ, van Hattum J, de Gast GC.

World J Gastroenterol. 2004 Jan 15;10(2):260-3.

11.

Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children.

Whittle H, Jaffar S, Wansbrough M, Mendy M, Dumpis U, Collinson A, Hall A.

BMJ. 2002 Sep 14;325(7364):569.

12.

Long-term effectiveness of infancy low-dose hepatitis B vaccine immunization in Zhuang minority area in China.

Li H, Li RC, Liao SS, Gong J, Zeng XJ, Li YP.

World J Gastroenterol. 1999 Apr;5(2):122-124.

13.

Risk and management of blood-borne infections in health care workers.

Beltrami EM, Williams IT, Shapiro CN, Chamberland ME.

Clin Microbiol Rev. 2000 Jul;13(3):385-407. Review.

14.

Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination.

Kibur M, af Geijerstamm V, Pukkala E, Koskela P, Luostarinen T, Paavonen J, Schiller J, Wang Z, Dillner J, Lehtinen M.

Sex Transm Infect. 2000 Feb;76(1):13-7.

15.

Hepatology.

McNair AN, Tibbs CJ, Williams R.

BMJ. 1995 Nov 18;311(7016):1351-5. Review. No abstract available.

Supplemental Content

Support Center